Head-to-Head drug trial for Tough-to-Treat kidney cancer
NCT ID NCT03541902
Summary
This study compares two existing drugs, cabozantinib and sunitinib, for patients with advanced, rare types of kidney cancer that have spread. The goal is to see which drug is better at controlling the cancer's growth and which has fewer side effects. Participants are randomly assigned to take one of the two drugs as a daily pill for as long as it helps them.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson Regional Care Center-Katy
Houston, Texas, 77094, United States
-
MD Anderson Regional Care Center-Sugar Land
Sugar Land, Texas, 77478, United States
Conditions
Explore the condition pages connected to this study.